Loading page…

Report overview

The report highlights Genmab's 2023 commercial expansion, including TALVEY becoming its eighth approved medicine. Consolidated revenue reached DKK 16,474 million, while the report also disclosed 2023 Scope 1 and Scope 2 emissions of 317 and 238 tCO2e. The climate section states that the 2022 footprint served as the baseline for Genmab's climate target.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Publication date: 14 February 2024
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Renewable energy
Employees
Women on the board
Women in management

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services